TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8623995

Group type: EXPERIMENTAL
Intervention: Group 1: 75 mg intramuscular diclofenac, 1000 mg intravenous metamizole, 5.3 +/- 1 mg epidural morphine, and 15-20 ml mepivacaine 1% administered 85 +/- 41 min before skin incision. Epidural analgesia maintained by injections of 0.1 ml.kg‐1.h‐1 mepivacaine 1%.
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Group 2: Balanced analgesia regimen before wound closure (221 +/- 86 min after skin incision).
Number of subjects: 142

Group type: COMPARATOR
Intervention: Group 3: Control group, did not receive any study substances.
Number of subjects: 142
Study: 1317828

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 3912367

Group type: EXPERIMENTAL
Intervention: Oral cephradine
Number of subjects: 84

Group type: COMPARATOR
Intervention: Intraperitoneal cephradine
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Other antibiotics after cephradine
Number of subjects: 84
Study: 30554883

Group type: EXPERIMENTAL
Intervention: Epidermal growth factor (EGF) applied directly without stripping of the perforation edge; n=26
Number of subjects: 44

Group type: COMPARATOR
Intervention: Observation only; n=18
Number of subjects: 44
Study: 28454806

Group type: EXPERIMENTAL
Intervention: IMR measurement after successful PPCI
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: IMR measurement
Number of subjects: 242
Study: 27321485

Group type: EXPERIMENTAL
Intervention: Surgical intervention model including antituberculosis drugs for at least 3 weeks, accurate wound assessment, complete excision of sinus tract and surrounding devitalized tissue, vacuum sealing drainage (VSD) for 1 to 2 weeks, followed by direct suture or grafting skin or flap.
Number of subjects: 43

Group type: COMPARATOR
Intervention: Routine dressing change every 3 days after initial antituberculosis drugs for at least 3 weeks.
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Test group
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study: 24911420

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Social Skills Training (CBSST)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Goal-Focused Supportive Contact (GFSC)
Number of subjects: 149
Study: 22577180

Group type: EXPERIMENTAL
Intervention: National Exercise Referral Scheme (NERS)
Number of subjects: 2160

Group type: COMPARATOR
Intervention: Normal care and brief written information
Number of subjects: 2160
Study: 19054492

Group type: EXPERIMENTAL
Intervention: Disruption of IS/OS junction
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Preoperative macular thickness
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Postoperative macular thickness
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Thickness difference and foveal contour
Number of subjects: 101
Study: 17315155

Group type: EXPERIMENTAL
Intervention: Low-dose cytarabine (Ara-C) (20 mg twice daily for 10 days)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Hydroxyurea with or without all-trans retinoic acid (ATRA)
Number of subjects: 217
Study: 15471181

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT) with 2 x 2000 impulses of 0.28 mJ/mm2 at an interval of two weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group with 2 x 2000 impulses of < 0.07 mJ/mm2 at an interval of two weeks
Number of subjects: 43
Study: 11576096

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 24
Study: 10021880

Group type: EXPERIMENTAL
Intervention: Children after cardiosurgical correction of ASD II
Number of subjects: 17

Group type: COMPARATOR
Intervention: Healthy children (control group)
Number of subjects: 17
Study: 8147360

Group type: EXPERIMENTAL
Intervention: Lactaid
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lactrase
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dairy Ease
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3170089

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation of 20 mg a day
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 89
Study: 31537225

Group type: EXPERIMENTAL
Intervention: Residual pump blood transfusion filtered by leukocyte depletion filter
Number of subjects: 40

Group type: COMPARATOR
Intervention: Residual pump blood transfusion without filtration
Number of subjects: 40
Study: 28183298

Group type: EXPERIMENTAL
Intervention: Nicotine-free and flavour-free e-liquid vaping for 1 hour
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (controlled environment)
Number of subjects: 0
Study: 25671594

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 14
Study: 24378322

Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (non-carriers)
Number of subjects: 17
Study: 21960182

Group type: EXPERIMENTAL
Intervention: Moderate dose of alcohol (0.65 g/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 19540365

Group type: EXPERIMENTAL
Intervention: Acu-TENS applied over acupuncture points Lieque and Dingchuan for 45 min prior to exercise (Group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acu-TENS applied prior to and throughout the exercise test (Group 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No electrical output from the device, mimicking Group 1 (Group 3)
Number of subjects: 30
Study: 17466492

Group type: EXPERIMENTAL
Intervention: Paliperidone ER 3 mg
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Paliperidone ER 9 mg
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Paliperidone ER 15 mg
Number of subjects: 618

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 618
Study: 15887835

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400mg single oral dose
Number of subjects: 12
Study: 12377959

Group type: EXPERIMENTAL
Intervention: EMO group (writing about deepest thoughts and feelings regarding breast cancer)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: POS group (writing about positive thoughts and feelings regarding breast cancer)
Number of subjects: 60

Group type: COMPARATOR
Intervention: CTL group (writing about facts of their breast cancer experience)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: EMO group and POS group
Number of subjects: 60
Study: 10530097

Group type: EXPERIMENTAL
Intervention: Braun Oral-B 3D Plaque Remover
Number of subjects: 44

Group type: COMPARATOR
Intervention: sonicare electric toothbrush
Number of subjects: 44
Study: 9307648

Group type: EXPERIMENTAL
Intervention: Topical 50 micrograms/ml latanoprost once daily from day 4 to day 18
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo eye drops once daily from day 4 to day 18
Number of subjects: 24
Study: 2036894

Group type: EXPERIMENTAL
Intervention: Total parathyroidectomy including autotransplantation (PTX + AT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Subtotal parathyroidectomy (PTX)
Number of subjects: 40
Study: 7294185

Group type: EXPERIMENTAL
Intervention: High dose of haloperidol
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Moderate dose of haloperidol
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Standard dose of haloperidol
Number of subjects: 44

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 44
Study: 31468106

Group type: EXPERIMENTAL
Intervention: Strength and balance training intervention (2 months, once-weekly home-based)
Number of subjects: 143
Study: 27828910

Group type: EXPERIMENTAL
Intervention: Ex‐Press Minishunt
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ahmed valve
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Deep sclerectomy
Number of subjects: 41
Study: 25424990

Group type: EXPERIMENTAL
Intervention: 20 mg atorvastatin daily
Number of subjects: 1152

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 1152
Study: 25954110

Group type: EXPERIMENTAL
Intervention: Bevacizumab + chemotherapy (AGITG MAX trial)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Bevacizumab + chemotherapy (TRACC registry)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Chemotherapy alone (AGITG MAX trial)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Chemotherapy alone (TRACC registry)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Bevacizumab + chemotherapy (TRACC registry, patients without peritoneal metastases)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Chemotherapy alone (TRACC registry, patients without peritoneal metastases)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Bevacizumab + chemotherapy (MAX trial)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Bevacizumab + chemotherapy (TRACC)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Bevacizumab + chemotherapy (NSWCC)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Chemotherapy duration
Number of subjects: 332
Study: 24255945

Group type: EXPERIMENTAL
Intervention: Interactive similarity maps
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hierarchical clustering approaches
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hierarchical two-means clustering
Number of subjects: 0
Study: 20922535

Group type: EXPERIMENTAL
Intervention: Low-calorie diet of 5.0 MJ/day for 1 week
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-calorie diet of 5.0 MJ/day for 5 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lean women (control group)
Number of subjects: 40
Study: 19036057

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17014595

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg twice daily (BID)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg once daily (QD)
Number of subjects: 449
Study: 12771595

Group type: EXPERIMENTAL
Intervention: Heated humidifier
Number of subjects: 11

Group type: COMPARATOR
Intervention: Heat and moisture exchanger
Number of subjects: 11
Study: 10665556

Group type: EXPERIMENTAL
Intervention: 6-week multidisciplinary rehabilitation programme (18 visits)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard medical management
Number of subjects: 200
Study: 9820371

Group type: EXPERIMENTAL
Intervention: Endoscopic hemostasis (heater probe, bipolar electrocoagulation, or injection sclerosis)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Medical‐surgical treatment
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Endoscopic hemostasis
Number of subjects: 155
Study: 8022739

Group type: EXPERIMENTAL
Intervention: Oral administration of methylprednisolone (500 mg for three consecutive days)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intravenous administration of methylprednisolone (500 mg for three consecutive days)
Number of subjects: 32
Study: 2555473

Group type: EXPERIMENTAL
Intervention: HIV-infected women
Number of subjects: 35

Group type: COMPARATOR
Intervention: Non-HIV-infected women
Number of subjects: 35
Study: 1101910

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (an antiandrogen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mesterolone (an androgen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31036002

Group type: EXPERIMENTAL
Intervention: Vignette depicting a potentially more well‐implemented mental health service
Number of subjects: 153

Group type: COMPARATOR
Intervention: Vignette depicting existing local psychiatric services
Number of subjects: 153
Study: 28490356

Group type: EXPERIMENTAL
Intervention: Miriplatin/DDP‐H combination therapy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Miriplatin monotherapy
Number of subjects: 19
Study: 25809331

Group type: EXPERIMENTAL
Intervention: Low dose CT colonography with enhanced scanning
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional dose CT colonography with enhanced scanning
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low dose CT colonography
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional dose CT colonography
Number of subjects: 120
Study: 24075764

Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg/day
Number of subjects: 26

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 26
Study: 21255459

Group type: COMPARATOR
Intervention: Standard catheter-directed thrombolysis (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ultrasound-accelerated thrombolysis (group B)
Number of subjects: 60
Study: 19450614

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease patients
Number of subjects: 41

Group type: COMPARATOR
Intervention: Healthy elderly controls
Number of subjects: 41
Study: 16813489

Group type: EXPERIMENTAL
Intervention: Value-expressive messages advocating testing for self-interest (own health)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Messages advocating testing for the goal of protecting one's partners
Number of subjects: 0
Study: 15098379

Group type: EXPERIMENTAL
Intervention: Raloxifene (Evista), one tablet daily, with or without food
Number of subjects: 7700
Study: 11783326

Group type: EXPERIMENTAL
Intervention: Tetramethylpyrazine (TMP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study: 9331324

Group type: EXPERIMENTAL
Intervention: Sphenopalatine ganglion blocks using 4% lidocaine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (sterile water)
Number of subjects: 61
Study: 7597427

Group type: EXPERIMENTAL
Intervention: Paclitaxel 135 mg/m2 infused as a single dose over 1 hour
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Paclitaxel divided into three doses infused over 1 hour on 3 consecutive days
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both infusion schedules
Number of subjects: 56
Study: 2512129

Group type: EXPERIMENTAL
Intervention: Aztreonam (300mg/kg/day i.v.; max 12g) + Amikacin (36mg/kg/day i.v.; max 1,500mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Ceftazidime (300mg/kg/day i.v.; max 12g) + Amikacin (36mg/kg/day i.v.; max 1,500mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Oral Ciprofloxacin (30mg/kg/day; max 1,500mg) for four weeks after initial therapy
Number of subjects: 42
Study: 31071100

Group type: EXPERIMENTAL
Intervention: Active Behavioural Physiotherapy Intervention (ABPI)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard Physiotherapy
Number of subjects: 28
Study: 28261001

Group type: EXPERIMENTAL
Intervention: Cranberry extract 1200 mg for 6 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 25380955

Group type: EXPERIMENTAL
Intervention: ECOM (Endotracheal Cardiac Output Monitor)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 100
Study: 24100691

Group type: EXPERIMENTAL
Intervention: Sparrow® drug‐eluting stent (DES)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sparrow® bare metal stent (BMS)
Number of subjects: 24
Study: 21331459

Group type: EXPERIMENTAL
Intervention: Cardiac (123)I‐MIBG uptake in de novo PD
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cardiovascular autonomic response on the Valsalva maneuver (VM)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure response (SBP) on head‐up tilt‐table testing (HUT)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Blood pressure overshoot in phase IV of the VM
Number of subjects: 26
Study: 18298503

Group type: EXPERIMENTAL
Intervention: Music therapy for 2 weeks
Number of subjects: 236

Group type: COMPARATOR
Intervention: General prenatal care (Control)
Number of subjects: 236
Study: 17201647

Group type: EXPERIMENTAL
Intervention: Citrus aurantium (herbal phenylephrine)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Phenylephrine (20 mg)
Number of subjects: 28
Study: 12492451

Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide (TD) 5 mg/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide (TD)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bumetanide (LD)
Number of subjects: 40
Study: 10791373

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus hyperthermia
Number of subjects: 358

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 358
Study: 9059313

Group type: EXPERIMENTAL
Intervention: Substance P
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Acetylcholine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Noradrenaline
Number of subjects: 8

Group type: COMPARATOR
Intervention: NG-Monomethyl-L-arginine
Number of subjects: 8
Study: 8110870

Group type: EXPERIMENTAL
Intervention: Glucerna
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Precitene Diabet
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both products (Glucerna and Precitene Diabet)
Number of subjects: 62
Study: 2859870

Group type: EXPERIMENTAL
Intervention: Indoramin (25 mg three times daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (beta blockers and nitrates continued unchanged)
Number of subjects: 15
Study: 30651294

Group type: EXPERIMENTAL
Intervention: Pap testing at the BHU (N = 160)
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Self HPV (self‐collection for HPV testing) (N = 161)
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Choice between self‐collection and HPV testing and Pap test at the local BHU (N = 162)
Number of subjects: 483
Study: 29846804

Group type: EXPERIMENTAL
Intervention: Digital Breast Tomosynthesis (DBT)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard Digital Mammography (DM)
Number of subjects: 144
Study: 26143058

Group type: EXPERIMENTAL
Intervention: Bitopertin
Number of subjects: 323

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 323
Study: 24977689

Group type: EXPERIMENTAL
Intervention: Nonnutritive sucking (NNS)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Oral stimulation (OS)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined NNS + OS
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 22672770

Group type: EXPERIMENTAL
Intervention: Solanezumab 400 mg weekly
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Solanezumab (various doses)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 20307678

Group type: EXPERIMENTAL
Intervention: Positively arousing musical piece after a 20-minute delay
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Negatively arousing musical piece after a 20-minute delay
Number of subjects: 127

Group type: COMPARATOR
Intervention: Positively arousing musical piece immediately post-learning
Number of subjects: 127

Group type: COMPARATOR
Intervention: Negatively arousing musical piece immediately post-learning
Number of subjects: 127

Group type: COMPARATOR
Intervention: Positively arousing musical piece after a 45-minute delay
Number of subjects: 127

Group type: COMPARATOR
Intervention: Negatively arousing musical piece after a 45-minute delay
Number of subjects: 127
Study: 18551725

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 365

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 365
Study: 16112299

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Haemopoietic-cell transplantation
Number of subjects: 357
Study: 12354424

Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy in hospitals with coronary revascularization capability
Number of subjects: 25515

Group type: COMPARATOR
Intervention: Fibrinolytic therapy in hospitals without coronary revascularization capability
Number of subjects: 25515
Study: 10519714

Group type: EXPERIMENTAL
Intervention: Clinical assessment by office based paediatricians
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Referral strategy
Number of subjects: 30
Study: 8624234

Group type: EXPERIMENTAL
Intervention: Colgate Micro Cleansing Tartar Control (MCTC) dentifrice
Number of subjects: 86

Group type: COMPARATOR
Intervention: Colgate original Tartar Control (TC) dentifrice
Number of subjects: 86
Study: 1970584

Group type: EXPERIMENTAL
Intervention: SK&F 104353 (800 micrograms inhaled)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Terfenadine (120 mg oral)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7069504

Group type: EXPERIMENTAL
Intervention: L-methionine (0.0605 mmoles/kg body weight)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N-acetyl-L-methionine (0.0605 mmoles/kg body weight)
Number of subjects: 0

Group type: COMPARATOR
Intervention: L-methionine and N-acetyl-L-methionine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N-acetyl-L-methionine
Number of subjects: 0
Study: 31615471

Group type: EXPERIMENTAL
Intervention: 99mTc-Rituximab
Number of subjects: 116

Group type: COMPARATOR
Intervention: 99mTc-sulfur colloid (fTcSC)
Number of subjects: 116
Study: 29071979

Group type: EXPERIMENTAL
Intervention: Electroacupuncture stimulation of HT acupoints (HT 1, HT 3, HT 4, HT 7) at 2 Hz, 2-5 mA for 6 min
Number of subjects: 20

Group type: COMPARATOR
Intervention: Electroacupuncture stimulation of non-acupoints for 6 min
Number of subjects: 20
Study: 26164674

Group type: EXPERIMENTAL
Intervention: 25 mg naltrexone
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 50 mg naltrexone
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 25118085

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation (Ca+Vit D, 2000mg and 1000IU/d) delivered as 2 snack bars per day for 9 weeks during Army BCT
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 23045575

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Physical Exercise (PE)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy and Physical Exercise (CBT/PE)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Waiting List Control
Number of subjects: 422
Study: 19998508

Group type: EXPERIMENTAL
Intervention: Fibrin sealant carrying ropivacaine in the gallbladder bed
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fibrin sealant in the gallbladder bed
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline in the gallbladder bed
Number of subjects: 60